| |
|
|
|
Aeglea BioTherapeutics Inc.  
|
|
7.31 -0.06 (-0.01%) |
04-22 16:00 |
|
Open: |
7.43 |
Pre close: |
7.37 |
Target:
|
9.53
|
|
High: |
7.43 |
Low: |
7.13 |
Resistance:
|
8.16
8.92
|
|
Volume: |
64,382 |
Market Cap: |
211M |
Support:
|
6.92
5.76
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
7.35
 |
MACD |
MACD(12,26):
|
-0.24  |
|
MA(20): |
7.83 |
Signal(12,26,9): |
-0.17 |
|
MA(100): |
8.12 |
Stochastic Oscillator |
%K(14,3):
|
20.96 |
|
MA(250): |
8.93 |
%D(3): |
22.07 |
|
Average Volume(K) |
3-Month: |
23640
|
52-Week |
High:
|
12.00 |
|
10-Days: |
21171 |
Low: |
6.31 |
|
RSI |
RSI(14):
|
37.95 |
Change(%): |
-7.5 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.130 |
Return on Equity (ttm) |
-75.3 |
Shares Out. (M) |
28.82 |
|
EPS Est. Current Year |
-2.070 |
Return on Assets (ttm) |
-66.3 |
Shares Float (M) |
28.06 |
|
EPS Est. Next Year |
-2.190 |
PEG Ratio |
0.00 |
% Held by Insiders |
3.50 |
|
EPS Est. Next Quarter |
-0.580 |
Qtrly Rev. Growth |
-100.0 |
% Held by Institutions |
68.00 |
|
Forward EPS |
-2.600 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
3.750 |
EBITDA (p.s.) |
0.000 |
P/E |
-3.43 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.95 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-32.19 |
P/S |
1108811520.00 |
|
Operating Margin |
-1169.32 |
Levered Free Cash Flow
(M) |
-17.01 |
P/CF |
-6.54 |
|
|
|
|
|
|
